Several anticancer agents targeting EGFR are under development, and some have been shown to exhibit therapeutic benefits in clinical studies of NSCLC, including tyrosine kinase inhibitors and monoclonal antibodies4,5. Here, EGFR is linked to non-small cell lung carcinoma.